SCHEMBL1661081

SCHEMBL1661081

O=C(CCc1ccccc1)NCc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.76
GAA P10253 1/20 0.75
ALDH1A1 P00352 4/20 0.73
L3MBTL1 Q9Y468 1/20 0.73
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
CYP1A2 P05177 1/20 0.71
CYP3A4 P08684 1/20 0.71
CYP2C9 P11712 1/20 0.71
CYP2C19 P33261 1/20 0.71
ERCC1 P07992 1/20 0.71
ERCC4 Q92889 1/20 0.71
LMNA P02545 1/20 0.66
HPGD P15428 1/20 0.66
ALOX15 P16050 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
HTT P42858 1/20 0.66
HDAC2 Q92769 1/20 0.66
HDAC8 Q9BY41 1/20 0.66
HDAC6 Q9UBN7 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8792470 0.91 ALDH1A1 (0.71) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL11269450 0.91 TRPV1 (0.82) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL1894742 0.91 TRPV1 (0.82) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL4075670 0.90 CYP1A2 (0.73) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL17229250 0.90 PLAAT3 (0.73) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL25046063 0.90 ALDH1A1 (0.71) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL29171592 0.90 L3MBTL1 (0.71) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL29171580 0.90 ALDH1A1 (0.71) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL1567314 0.90 SELL (0.69) TRPV1GAAALDH1A1L3MBTL1MEN1
SCHEMBL4071835 0.90 CYP1A2 (0.73) TRPV1GAAALDH1A1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0828721-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1998-03-18 EP claimed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO claimed
CN-116121782-B Method for synthesizing tellurium-containing oxazolidinone compound by electrochemically fixing carbon dioxide and application thereof 桂林电子科技大学 2025-04-22 CN disclosed
CN-116574154-A Cyclic peptide-lenalidomide PROTAC derivative, preparation method thereof and application thereof in anticancer drugs 哈尔滨师范大学 2023-08-11 CN disclosed
CN-116121782-A Method for synthesizing tellurium-containing oxazolidinone compound by electrochemically fixing carbon dioxide and application thereof 桂林电子科技大学 2023-05-16 CN disclosed
CN-110590691-B Method for preparing tetra-substituted vinyl oxazolidine-2, 4-diketone from carbon dioxide 常州大学 2022-05-31 CN disclosed
CN-110066254-B Preparation method of isothiazole-3-ketone compound 温州大学 2021-03-19 CN disclosed
CN-107790186-B Novel decamethyl cyclopentadienyl zirconium complex and preparation method and application thereof 山西医科大学 2020-10-30 CN disclosed
CN-109180601-B Organic amine catalyzed CO2Method for synthesizing 2, 4-oxazolidinedione compound 大连理工大学 2020-08-21 CN disclosed
CN-110590691-A Method for preparing tetra-substituted vinyl oxazolidine-2, 4-diketone from carbon dioxide 常州大学 2019-12-20 CN disclosed
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
US-20040259890-A1 Spiro compounds MSD K.K. (JP) 2004-12-23 US disclosed
EP-1122245-B1 2-Amino-benzoxazinones for the treatment of viral infections SEARLE & CO (US) 2004-07-07 EP disclosed
EP-1415986-A1 SPIRO COMPOUNDS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
EP-0828721-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1998-03-18 EP disclosed
EP-0773929-A1 PIPERIDINE DERIVATIVES AS NEUROKININ ANTAGONISTS SCHERING CORPORATION (US) 1997-05-21 EP disclosed
WO-1996039386-A1 PIPERIDINE DERIVATIVES AS NEUROKININ ANTAGONISTS SCHERING CORPORATION (US) 1996-12-12 WO disclosed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, ACE2 TRPV1 2053/4885GAA 2790/4885ALDH1A1 1858/4885
US-20040259890-A1 Spiro compounds OPRD1, PER2, OPRK1 TRPV1 682/4885GAA 2357/4885ALDH1A1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.